Stay up to date on NKGen Biotech’s company news and announcements.

Press Releases

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company

NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases

NKGen Biotech Announces Appointment of Chief Financial Officer

NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer

Subscribe to NKGen News Updates

* indicates required

NKGen Biotech Events

Check back soon for upcoming events!

NKGen on Social Media

Follow NKGen on social media to keep up-to-date on the latest company news and the science of Natural Killer cells!